Sildodime M 50 tablet is a combination of a β3-adrenoceptor agonist (Mirabegron) and an alpha-1 blocker (Silodosin) used for managing overactive bladder and lower urinary tract symptoms associated with BPH.
It works by relaxing bladder and prostate smooth muscles, improving urinary flow, reducing urgency, frequency, and nocturia, and providing better bladder control.
This tablet is widely prescribed in overactive bladder syndrome, benign prostatic hyperplasia, and urinary retention management, helping adult patients achieve improved urinary comfort and daily convenience.
With strong clinical relevance in urology care, growing acceptance among healthcare professionals, and rising demand in bladder and BPH management, this formulation strengthens institutional and outpatient therapy portfolios and supports sustained therapeutic utilization.
Some patients may experience headache, dizziness, increased blood pressure, mild gastrointestinal discomfort, or nasal congestion. Rarely, serious cardiovascular effects, allergic reactions, or urinary retention may occur and should be reported to a healthcare professional immediately.
Sildodime M 50 Tablet is indicated for adult patients experiencing symptoms of overactive bladder, such as urinary urgency, frequency, and urge incontinence, especially when accompanied by benign prostatic hyperplasia. The combination of Mirabegron and Silodosin helps improve bladder storage, reduce urinary discomfort, and enhance overall urinary flow, providing comprehensive management of bladder and prostate-related urinary issues.
This medicine should be taken under medical supervision. Patients with severe hypertension, heart disease, liver or kidney impairment, or other urological disorders should consult their doctor before use. Adhere strictly to the prescribed dosage for safe and effective treatment.
Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.